Antihyperalgesic effect of the cannabinoid agonist WIN55,212-2 is mediated through an interaction with spinal metabotropic glutamate-5 receptors in rats

Neuroscience Letters

Volumn 358, Issue 1, 2004, Pages 21-24

  Hama, Aldric T ^a   Urban, Mark O ^a,b  

^a Merck Laboratories   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hyperalgesia; Intrathecal; Neuropathic pain; Spinal cord

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR AGONIST; METABOTROPIC RECEPTOR 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EVALUATION; FOOT; HYPERALGESIA; INJECTION; MALE; NERVE LIGATION; NONHUMAN; PERIPHERAL NERVE INJURY; PRESSURE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RAT; SCIATIC NERVE; SPINAL CORD DORSAL HORN;

ANIMALS; CANNABINOIDS; HYPERALGESIA; MALE; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, METABOTROPIC GLUTAMATE; SCIATIC NEUROPATHY; SPINAL CORD;

EID: 1542285335     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2003.12.111     Document Type: Article

References (11)

1. 3H]- Methoxymethyl-MTEP binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303:2002;1044-1051.
2. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 33:1988;87-107.
3. Bridges D., Ahmad K., Rice A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol. 133:2001;586-594.
4. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450.
5. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
6. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221:1997;157-160.
7. Malan T.P. Jr, Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
8. Palazzo E., Marabese I., de Novellis V., Oliva P., Rossi F., Berrino L., Maione S. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology. 40:2001;319-326.
9. Richardson J.D. Cannabinoids modulate pain by multiple mechanisms of action. J. Pain. 1:2000;2-14.
10. Walker K., Bowes M., Panesar M., Davis A., Gentry C., Kesingland A., Gasparini F., Spooren W., Stoehr N., Pagano A., Flor P.J., Vranesic I., Lingenhoehl K., Johnson E.C., Varney M., Urban L., Kuhn R. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 40:2001;1-9.
11. Yaksh T., Rudy T. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1976;1031-1036.